Ann Rheum Dis:RA患者心血管疾病风险预测:改良算法并无优势

2015-02-21 梁怀彬 译 MedSci原创

目前对于类风湿关节炎(RA)患者的心血管疾病(CVD)风险预测计算方法仍很不完善,对这类人群的风险评估需要采取特异性的心血管疾病风险预测方法。研究者根据RA患者的特异性心血管风险决定因素对“冠脉疾病风险系统评估方法”(the Systematic COronary Risk Evaluation ,SCORE)进行改良,并评估改良后的SCORE评分对CVD预测的准确性。 主要观察终点是首次CVD发

目前对于类风湿关节炎(RA)患者的心血管疾病(CVD)风险预测计算方法仍很不完善,对这类人群的风险评估需要采取特异性的心血管疾病风险预测方法。研究者根据RA患者的特异性心血管风险决定因素对“冠脉疾病风险系统评估方法”(the Systematic COronary Risk Evaluation ,SCORE)进行改良,并评估改良后的SCORE评分对CVD预测的准确性。 主要观察终点是首次CVD发生,重新校准后的SCORE算法通过对传统的CVD风险因素进行重新加权得到,改良后的SCORE算法的改良之处在于添加进了一些新的潜在预测因素,研究者对经过校准后SCORE算法和改良后SCORE算法效能进行了评估。 收集的1016名RA患者中103人随后发生了CVD,重新校准后SCORE算法和改良后的SCORE算法和原算法相比对CVD的预测识别率相当。Hosmer–Lemeshow 测试结果显示三种算法都对Nijmegen队列和其他RA队列有着较差的一致性。改良后的SCORE算法提高了无CVD事件发生人群中的CVD风险估计值,但是在将来会发生CVD事件的人群中未显示出预测和相应的识别能力。 本研究

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2011956, encodeId=1be72011956b1, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jul 19 20:55:00 CST 2015, time=2015-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472955, encodeId=3ffd14e2955c0, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Feb 23 03:55:00 CST 2015, time=2015-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485906, encodeId=eea51485906bf, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Mon Feb 23 03:55:00 CST 2015, time=2015-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497869, encodeId=f1f2149e869b9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Feb 23 03:55:00 CST 2015, time=2015-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16752, encodeId=684f16e52c8, content=长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Mon Feb 23 01:06:00 CST 2015, time=2015-02-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2011956, encodeId=1be72011956b1, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jul 19 20:55:00 CST 2015, time=2015-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472955, encodeId=3ffd14e2955c0, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Feb 23 03:55:00 CST 2015, time=2015-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485906, encodeId=eea51485906bf, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Mon Feb 23 03:55:00 CST 2015, time=2015-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497869, encodeId=f1f2149e869b9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Feb 23 03:55:00 CST 2015, time=2015-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16752, encodeId=684f16e52c8, content=长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Mon Feb 23 01:06:00 CST 2015, time=2015-02-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2011956, encodeId=1be72011956b1, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jul 19 20:55:00 CST 2015, time=2015-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472955, encodeId=3ffd14e2955c0, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Feb 23 03:55:00 CST 2015, time=2015-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485906, encodeId=eea51485906bf, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Mon Feb 23 03:55:00 CST 2015, time=2015-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497869, encodeId=f1f2149e869b9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Feb 23 03:55:00 CST 2015, time=2015-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16752, encodeId=684f16e52c8, content=长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Mon Feb 23 01:06:00 CST 2015, time=2015-02-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2011956, encodeId=1be72011956b1, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jul 19 20:55:00 CST 2015, time=2015-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472955, encodeId=3ffd14e2955c0, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Feb 23 03:55:00 CST 2015, time=2015-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485906, encodeId=eea51485906bf, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Mon Feb 23 03:55:00 CST 2015, time=2015-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497869, encodeId=f1f2149e869b9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Feb 23 03:55:00 CST 2015, time=2015-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16752, encodeId=684f16e52c8, content=长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Mon Feb 23 01:06:00 CST 2015, time=2015-02-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2011956, encodeId=1be72011956b1, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jul 19 20:55:00 CST 2015, time=2015-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472955, encodeId=3ffd14e2955c0, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Feb 23 03:55:00 CST 2015, time=2015-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485906, encodeId=eea51485906bf, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Mon Feb 23 03:55:00 CST 2015, time=2015-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497869, encodeId=f1f2149e869b9, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Feb 23 03:55:00 CST 2015, time=2015-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16752, encodeId=684f16e52c8, content=长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Mon Feb 23 01:06:00 CST 2015, time=2015-02-23, status=1, ipAttribution=)]
    2015-02-23 午夜星河

    长知识

    0

相关资讯

Arthritis Care Res:RA早期手骨密度下降可预测侵蚀风险增高

尽管改变病情抗风湿药(DMARDs)的联用使类风湿性关节炎(RA)得到了更好的控制,但仍有一些患者出现进展性侵蚀性病变。早期治疗对患者预后有着积极的意义,研究表明,在“窗口”期对RA进行早期强化治疗可获得良好结局,能减少患者侵蚀性病变及继发残疾的发生。此外,在极早期(前12周)进行RA治疗是12个月时无侵蚀性进展的最好预测指标。对有进展性关节损伤风险的患者做到早期诊断,可让他们提前接受包括生物制剂

PNAS:新型疗法能彻底治愈类风湿性关节炎

类风湿性关节炎是一种引发机体许多关节疼痛炎症的一种疾病,其会引发关节囊肿胀,这种疾病往往会破坏机体的软骨组织和骨质;在世界范围内类风湿性关节炎影响着0.5%至1%的人群的健康,到目前为止医生们已经可以使用多种药物来缓解或者阻断该疾病的发展。近日,刊登在国际杂志PNAS上的一篇研究论文中,来自苏黎世联邦理工学院的研究人员通过研究开发了一种新型疗法,其在治疗患类风湿性关节炎小鼠的功效上可以达到一

PNAS:彻底治愈类风湿性关节炎的新型疗法

类风湿性关节炎是一种引发机体许多关节疼痛炎症的一种疾病,其会引发关节囊肿胀,这种疾病往往会破坏机体的软骨组织和骨质;在世界范围内类风湿性关节炎影响着0.5%至1%的人群的健康,到目前为止医生们已经可以使用多种药物来缓解或者阻断该疾病的发展。近日,刊登在国际杂志PNAS上的一篇研究论文中,来自苏黎世联邦理工学院的研究人员通过研究开发了一种新型疗法,其在治疗患类风湿性关节炎小鼠的功效上可以达到

类风湿性关节炎八类用药

类风湿性关节炎是一种异质性疾病,所有人群均有可能会患上此病,它会引发口腔溃疡、关节脱位、库欣综合征等疾病,类风湿性关节炎的种类很多,表面上表现虽相似,但有不同类型,因而病情轻重、发展、预后、结局都可有所不同,尽管临床上区分这些类型还有困难,但从概念上说,是否所有类风湿性关节炎都一样治疗,就很值得商榷了。 据数据显示,研究人员对532例类风湿性关节炎患者追踪的结果表明,其中症状出现少于6个月者

Ther Adv Musculoskel Dis:通过皮下治疗类风湿性关节炎的生物药剂

背景 尚未用于治疗类风湿性关节炎的生物制剂进行等效分析其有效性。等价测试有一个特定的科学兴趣,但也可以用于决定相比于同类药理的药剂进行采购招标是否可行。 方法 我们的搜索更新至2014年8月的文献。我们的方法是结合标准两两分析、贝叶斯网络分析和等效性测试。检查潜在等效性的药物有依那西普,阿达木单抗,高利单抗,赛妥珠单抗,塔西单抗等都与甲氨蝶呤(MTX)联合使用。对照治疗是甲氨蝶呤单药治疗。治疗终

Rheumatology:类风湿性关节炎应激免疫应答过程

应激是促进慢性炎症性疾病发展的潜在因素之一,可导致类风湿性关节炎(RA)及银屑病病情进展。荷兰奈梅亨大学医学中心de Brouwer SJ等对RA和银屑病应激状态的免疫应答情况进行研究,该研究结果发表在2014年10月《风湿病学》杂志上。 该研究对病情进展过程中的循环细胞因子水平进行检测,探索性对比急性应激对这些细胞因子的影响,并探讨RA患者、银屑病患者及正常机体中的应激应答反应情况。 纳入研